Company Legal Name
Latest Valuation
Founded Year
Headquarter
Tessera Therapeutics develops advanced biotechnology tools for writing precise, permanent genetic changes to treat inherited diseases. Founded in 2018 and headquartered in Cambridge, Massachusetts, the company positions itself at the forefront of gene editing technology, focusing on creating therapeutic solutions that go beyond traditional approaches by enabling targeted genetic modifications. Tessera's proprietary platform addresses the significant medical need for treating genetic disorders through permanent genetic corrections rather than temporary interventions. The company continues to advance its gene writing capabilities, working toward clinical applications that could transform treatment paradigms for patients with inherited genetic conditions requiring precise therapeutic interventions.
Revenue & Revenue Growth Share
Revenue
Revenue Growth
Available in most regions; subject to local regulations.
Open to non-accredited investors with KYC/AML compliance. U.S. investors must meet SEC requirements.
$10 per token, enabling fractionalized access to Pre-IPO shares.
Mandatory identity (KYC) and proof of funds checks.
Variable, applied to investment amounts.
Charged on realized profits.
Tokens may be locked for 6–12 months; resale depends on secondary market liquidity.
Prices reflect past funding rounds, not guaranteed future value.
Biotech depends on regulatory approvals; fintech faces evolving digital asset rules.
Blockchain or custodian issues could delay transfers or verification.
Changing laws may affect tradability or taxation.
